COMP <GO>
VRXA vs CUE // PIOTROSKI F-SCORE QUALITY
Veraxa Biotech AG (NASDAQ) VS. Cue Biopharma Inc. (NASDAQ) • 15-METRIC TALLY: VRXA 2
— CUE 0
■ METRIC PARITY
LAST: $1.14 (+0.89%) • MKT CAP: $159.8M
piotroski-score
—
LAST: $20.87 (-2.70%) • MKT CAP: $155.8M
piotroski-score
4/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (VRXA VS. CUE)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | VRXA | CUE | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | — | -35.00% | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | -14.03% | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -60.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | 180.00% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | — | 4/9 | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 47.8 | 46.7 | +1.08 | VRXA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $159.8M | $155.8M | $4.0M | VRXA | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | VRXA REV | CUE REV | VRXA GROSS % | CUE GROSS % | VRXA FCF | CUE FCF |
|---|---|---|---|---|---|---|
| FY 2025 | — | $27.5M | — | — | — | -$21.9M |
| FY 2024 | — | $9.3M | — | — | — | -$36.4M |
| FY 2023 | — | $5.5M | — | — | — | -$40.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
VRXA // BETA —
CUE // BETA —